STAAR SURGICAL CO — Director's Dealing 2021

May 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: STAAR SURGICAL CO (STAA)
CIK: 0000718937
Period of Report: 2021-05-11

Reporting Person: Hansen Graydon C. (Sr. VP, Global Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-11	Common Stock	M	1050	$35.98	Acquired	15428	Direct
2021-05-11	Common Stock	M	10025	$27.53	Acquired	25453	Direct
2021-05-11	Common Stock	S	11075	$111.61	Disposed	14378	Direct
2021-05-12	Common Stock	S	5531	$110.74	Disposed	8847	Direct
2021-05-12	Common Stock	M	375	$29.80	Acquired	9222	Direct
2021-05-12	Common Stock	M	231	$35.98	Acquired	9453	Direct
2021-05-12	Common Stock	M	348	$16.15	Acquired	9801	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-11	Common Stock Options	$35.98	M	1050	Disposed	2029-03-13	Common Stock (1050)	Direct
2021-05-11	Common Stock Options	$27.53	M	10025	Disposed	2030-03-19	Common Stock (10025)	Direct
2021-05-12	Common Stock Options	$29.80	M	375	Disposed	2028-06-13	Common Stock (375)	Direct
2021-05-12	Common Stock Options	$35.98	M	231	Disposed	2029-03-13	Common Stock (231)	Direct
2021-05-12	Common Stock Options	$16.15	M	348	Disposed	2028-03-14	Common Stock (348)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.08 to $113.18, inclusive.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $112.29, inclusive.

F3: The options granted become exercisable as follows: 1/3 on 3/14/2020 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/14/2022.

F4: The options granted become exercisable as follows: 1/3 on 3/20/2021 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/20/2023.

F5: The options granted become exercisable as follows: 1/3 on 6/14/2019 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 6/14/2021.

F6: The options granted become exercisable as follows: 1/3 on 3/15/2019 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/15/2021.